KOTARO SASAKI
Medical Practice in Pittsburgh, PA
License number
Pennsylvania MT193660
Category
Medicine
Type
Graduate Medical Trainee
Address
Address
Pittsburgh, PA 15213
Professional information
See more information about KOTARO SASAKI at trustoria.com
Dr. Kotaro Sasaki, Pittsburgh PA - MD (Doctor of Medicine)
Dr. Kotaro Sasaki, Pittsburgh PA - MD (Doctor of Medicine)
Specialties:
Anatomic Pathology
Address:
A711 Scaife Hl, Pittsburgh 15261
(412) 802-6013 (Phone), (412) 802-6079 (Fax)
(412) 802-6013 (Phone), (412) 802-6079 (Fax)
Certifications:
Anatomic Pathology, 2011
Awards:
Healthgrades Honor Roll
Languages:
English
Th1-Associated Micrornas And Their Use For Tumor Immunotherapy
Th1-Associated Micrornas And Their Use For Tumor Immunotherapy
US Patent:
2013034, Dec 26, 2013
Filed:
Jun 18, 2013
Appl. No.:
13/920357
Inventors:
Gary Kohanbash - Pittsburgh PA, US
Kotaro Sasaki - Pittsburgh PA, US
Kotaro Sasaki - Pittsburgh PA, US
International Classification:
A61K 35/14
US Classification:
424 9321
Abstract:
Described herein is the identification of miRNAs (miRs) that are up-regulated in Th1 cells compared to Th2 cells (referred to herein as Th1-associated miRs). In particular, the miR-17-92 gene cluster was found to exhibit significantly greater expression in Th1 cells. Over-expression of miR-17-92 in T cells promotes the Th1 phenotype. Thus, the use of Th1-associated miRs for cancer immunotherapy is described. Provided herein are isolated T cells containing a heterologous nucleic acid molecule encoding a Th1-associated miR, such as the miR17-92 gene cluster, or a portion thereof. Further provided is a method of treating cancer in a subject by administering to the subject an isolated T cell as disclosed herein. Also provided is a method of treating a subject with cancer by transfecting isolated T cells obtained from the subject with a heterologous nucleic acid molecule encoding a Th1-associated miR and administering the transfected T cells to the subject.
Th1-Associated Micrornas And Their Use For Tumor Immunotherapy
Th1-Associated Micrornas And Their Use For Tumor Immunotherapy
US Patent:
8486911, Jul 16, 2013
Filed:
Aug 7, 2012
Appl. No.:
13/568457
Inventors:
Hideho Okada - Pittsburgh PA, US
Gary Kohanbash - Pittsburgh PA, US
Kotaro Sasaki - Pittsburgh PA, US
Gary Kohanbash - Pittsburgh PA, US
Kotaro Sasaki - Pittsburgh PA, US
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:
A01N 43/04, A61K 31/70
US Classification:
514 44A, 514 44 R
Abstract:
Described herein is the identification of miRNAs (miRs) that are up-regulated in Th1 cells compared to Th2 cells (referred to herein as Th1-associated miRs). In particular, the miR-17-92 gene cluster was found to exhibit significantly greater expression in Th1 cells. Over-expression of miR-17-92 in T cells promotes the Th1 phenotype. Thus, the use of Th1-associated miRs for cancer immunotherapy is described. Provided herein are isolated T cells containing a heterologous nucleic acid molecule encoding a Th1-associated miR, such as the miR17-92 gene cluster, or a portion thereof. Further provided is a method of treating cancer in a subject by administering to the subject an isolated T cell as disclosed herein. Also provided is a method of treating a subject with cancer by transfecting isolated T cells obtained from the subject with a heterologous nucleic acid molecule encoding a Th1-associated miR and administering the transfected T cells to the subject.
Th1-Associated Micrornas And Their Use For Tumor Immunotherapy
Th1-Associated Micrornas And Their Use For Tumor Immunotherapy
US Patent:
2010032, Dec 23, 2010
Filed:
Jun 17, 2010
Appl. No.:
12/818016
Inventors:
Hideho Okada - Pittsburgh PA, US
Gary Kohanbash - Pittsburgh PA, US
Kotaro Sasaki - Pittsburgh PA, US
Gary Kohanbash - Pittsburgh PA, US
Kotaro Sasaki - Pittsburgh PA, US
International Classification:
A61K 35/12, C12N 5/0783, A61P 35/00
US Classification:
424 9321, 435325
Abstract:
Described herein is the identification of miRNAs (miRs) that are up-regulated in Th1 cells compared to Th2 cells (referred to herein as Th1-associated miRs). In particular, the miR-17-92 gene cluster was found to exhibit significantly greater expression in Th1 cells. Over-expression of miR-17-92 in T cells promotes the Th1 phenotype. Thus, the use of Th1-associated miRs for cancer immunotherapy is described. Provided herein are isolated T cells containing a heterologous nucleic acid molecule encoding a Th1-associated miR, such as the miR17-92 gene cluster, or a portion thereof. In some embodiments, the T cell is a tumor antigen (TA)-specific T cell, such as a TA-specific CTL. Further provided is a method of treating cancer in a subject by selecting a subject with cancer and administering to the subject an isolated T cell as disclosed herein. Also provided is a method of treating a subject with cancer by transfecting isolated T cells obtained from the subject with a heterologous nucleic acid molecule encoding a Th1-associated miR and administering the transfected T cells to the subject. In some embodiments of the method, the heterologous nucleic acid molecule encodes the miR-17-92 transcript or a portion thereof. In some embodiments, the isolated T cell is a TA-specific T cell, such as a CTL.